Premenstrual Syndrome Treatment Market: Increase in Prevalence of PMS and Premenstrual Dysphoric Disorder (PMDD) to Propel the Market

Premenstrual Syndrome Treatment Market Outlook 2031

-The global premenstrual syndrome treatment market was valued at US$ 1.3 Bn in 2021
-The global market is projected to grow at a CAGR of 3.4% from 2022 to 2031
-The global premenstrual syndrome treatment market is anticipated to reach more than US$ 1.9 Bn by the end of 2031

Premenstrual Syndrome Treatment Market Introduction

Premenstrual syndrome, or PMS, is the term used to describe a group of physical and psychological symptoms that develop one to two weeks prior to the start of a woman's menstrual cycle. These symptoms include acne, sore breasts, mood swings, bloating, exhaustion, and irritability. The market is growing as a result of factors such as increased public knowledge of premenstrual syndrome symptoms and treatments, a larger target market, rising PMS drug demand, and accessibility of medications. A majority of women who have PMS are typically in their 30s.

Read Report Overview @ https://www.transparencymarketresearch.com/premenstrual-syndrome-market.html

Women are susceptible to adverse events caused due to the administration of antidepressants, diuretics, and nonsteroidal anti-inflammatories. Thus, manufacturers operating in the premenstrual syndrome treatment or dysmenorrhea treatment market are focusing on vitamin supplements and herbal medicines to ease premenstrual syndrome (PMS) in women. Supplements made from micronutrients such as calcium, magnesium, vitamin B6, and potassium are being highly publicized for the effective management of premenstrual syndrome.

However, many supplements are not regulated by the FDA (Food & Drug Administration) and could interfere with prescription medications. Hence, companies in the premenstrual syndrome treatment market are educating women to seek a doctor's consultation to avoid risks of the side-effects. Mood-boosting supplements induced with vitamin B6 are in high demand. Organic chasteberry in nutritional supplements is gaining popularity for easing anxiety and depression.

Get Sample Copy of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2922

Increase in Prevalence of PMS and Premenstrual Dysphoric Disorder (PMDD) to Propel Global Premenstrual Syndrome Treatment Market

Almost three in four women experience premenstrual syndrome at some point in their lives. According to a study that was published in the General Psychiatry Journal 2020, 90% of women of reproductive age were likely to experience various premenstrual symptoms, ranging in severity from mild to severe. Around 20% to 40% of women experience premenstrual syndrome. Rising incidence of premenstrual dysphoric disorder (PMDD) in different parts of the world is one of the primary factors fueling the premenstrual syndrome treatment market size. Sedentary lifestyles and demanding schedules of the female working population could be blamed for this. Furthermore, growing awareness among the general public regarding luteal phase therapy or different treatment options for PMS and other related disorders is also driving the market. Pharmaceutical companies are releasing drugs that help the body's pH level stay balanced while having few side-effects. Premenstrual syndrome treatment is gaining popularity, which in turn is boosting the market.

High Demand for Micronutrient Supplements Fueling Global Premenstrual Syndrome Treatment Market

Use of antidepressants, diuretics, and nonsteroidal anti-inflammatory drugs could have negative side-effects on women. Manufacturers operating in the premenstrual syndrome treatment market are concentrating on vitamin supplements and herbal medications to help women with premenstrual syndrome (PMS). Furthermore, acupuncture-related products are gaining traction for treating pain.

Get Report Methodology @ https://www.transparencymarketresearch.com/sample/sample.php?flag=RRM&rep_id=2922

It is widely known that taking supplements containing micronutrients such as calcium, magnesium, vitamin B6, and potassium could effectively treat premenstrual syndrome. The FDA (Food & Drug Administration) does not regulate various supplements; however, they could conflict with prescription drugs. Businesses in the premenstrual syndrome treatment market are educating women to consult a doctor in order to reduce the risk of side-effects. Vitamin B6-based supplements that improve mood are in high demand. Organic chaste berry nutritional supplements are rising in popularity for reducing anxiety and depression.

High Preference for Oral Contraceptives & Ovarian Suppression Agents to Reduce Premenstrual Syndrome Symptoms

In terms of drug type, the global premenstrual syndrome treatment market has been split into antidepressants, diuretics, pain relievers, oral contraceptives & ovarian suppression agents, and others. Combined oral contraceptives may reduce overall premenstrual symptomatology in women with premenstrual syndrome or premenstrual dysphoric disorder. Therefore, the oral contraceptives & ovarian suppression drugs segment held a majority of the premenstrual syndrome treatment market share.

Get Custom Research Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=2922

Regional Outlook of Global Premenstrual Syndrome Treatment Market

North America accounted for a significant share of the global premenstrual syndrome treatment in 2021. According to an article published by National Library of Medicine, in the U.S., approximately 70% to 90% of women in the reproductive age group reported at least some premenstrual discomfort. Approximately one-third of these women have symptoms that are bothersome enough to qualify for the diagnosis of PMS. The most severe form of premenstrual symptom complex, PMDD, has been noted in 3% to 8% of these PMS cases. The market in Asia Pacific is estimated to rise at a notable CAGR during the forecast period due to increasing awareness regarding premenstrual syndrome treatment in the region.

Analysis of Key Players in Global Premenstrual Syndrome Treatment Market

The report concludes with the company profiles section, which includes information about key players in the global premenstrual syndrome treatment market. Expansion of product portfolio and mergers & acquisitions are prominent strategies adopted by key players in the market. Allergan (AbbVie, Inc.), Bayer AG, Fresenius Kabi AG, Johnson & Johnson Services, Inc., Lilly, Mylan N.V. (Viatris Inc.), Pfizer, Inc., and Teva Pharmaceutical Industries Ltd. are prominent players in the global premenstrual syndrome treatment market.

Contact

Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: sales@transparencymarketresearch.com

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

This release was published on openPR.